17.90
+0.46(+2.64%)
Currency In USD
| Previous Close | 17.44 |
| Open | 17.5 |
| Day High | 17.9 |
| Day Low | 16.89 |
| 52-Week High | 29.98 |
| 52-Week Low | 6.53 |
| Volume | 115,995 |
| Average Volume | 225,806 |
| Market Cap | 157.07M |
| PE | 20.34 |
| EPS | 0.88 |
| Moving Average 50 Days | 18.2 |
| Moving Average 200 Days | 14.05 |
| Change | 0.46 |
If you invested $1000 in Seres Therapeutics, Inc. (MCRB) 10 years ago, it would be worth $514.07 as of December 05, 2025 at a share price of $17.9. Whereas If you bought $1000 worth of Seres Therapeutics, Inc. (MCRB) shares 5 years ago, it would be worth $708.91 as of December 05, 2025 at a share price of $17.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
GlobeNewswire Inc.
Oct 30, 2025 11:00 AM GMT
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m.
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
GlobeNewswire Inc.
Oct 29, 2025 11:00 AM GMT
Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infectionsCAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therape
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase 1b trial will be featured in